Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

On 24-25 Jan 2019, investigators met in Bangkok to launch the Developing Triple Artemisinin-based Combination Therapies (DeTACT) Project. Led by MORU and funded by UKaid and the UK Department for International Development (DfID), DeTACT is a large, 14 site trial in 8 African and 5 Asian countries that will study the efficacy, safety and tolerability of two Triple Artemisinin Combination Therapy (TACT) combinations, using combinations of existing antimalarial drugs.

Various investigators

DeTACT will also project the impact of TACTs on controlling the spread or emergence of multi-drug-resistant P. falciparum malaria leading to its elimination, and examine the ethical and commercial considerations of using TACTs across the malaria endemic world.

DeTACT is particularly urgent: strains of P. falciparum malaria parasite highly resistant to artemisinins, our most effective antimalarial drugs, have rapidly spread out of Cambodia and across SE Asia. These malaria ‘superbugs’ have caused a large increase in treatment failures in malaria patients across the Greater Mekong Subregion, and if they emerge in Africa, put millions, especially children under 5, at risk.

“DeTACT is a very important study: Increasing drug resistance in Southeast Asia jeopardizes the treatment of P. falciparum malaria, a potential fatal disease, and malaria elimination is only possible if we have effective drugs to treat the disease,” said Oxford Prof. Arjen Dondorp, Head of Malaria at MORU and principal investigator for DeTACT. “These TACTs can provide an effective and safe malaria treatment, using a combination of already available antimalarial drugs.”

The DeTACT trials will compare two widely used drug combinations (artemether-lumefantrine and arterolane-piperaquine) against two TACTs constituted of one additional drug added to each of these combinations (amodiaquine and mefloquine, respectively).

Based on preliminary results from the recently completed TRACII trials which recruited over 1,000 subjects with uncomplicated falciparum malaria, TACTs already appear to be safe and highly efficacious even against multi-drug resistant falciparum malaria currently prevalent in parts of SE Asia. Before such combinations can be recommended for more widespread use, especially in highly endemic regions of Africa where children are most affected by malaria, their safety and tolerability must be verified.

Stringent assessments to identify cardiac, hepatic, renal or bone marrow toxicity or other study drugs-related dysfunctions will be complemented by predictive mathematical modelling to analyse TACTs’ costs and expected benefits and assess their potential to delay the emergence or spread of drug-resistant P. falciparum malaria.

At the meetings, investigators from the Africa and Asia study sites and researchers leading the complementary work packages and sub-studies presented plans to implement their studies and analyses.

The bioethics component of DeTACT will document patient, practitioner and policy maker views and attitudes on deploying TACTs. It will use focus groups and interviews to identify potential barriers to TACT acceptability and deployment and address ethical issues arising from introducing TACTs to treat African children where current ACT therapy is still efficacious. This work will be supplemented by assessments of the market positioning within and outside donor funded malaria services, and potential market uptake in different malaria epidemiological settings.

Dr Chanaki Amaratunga will jointly coordinate DeTACT with Dr Mehul Dhorda. Chanaki will coordinate the project and focus on the Asia trials and the complementary work packages, while Mehul will coordinate the Africa trials and related activities. DeTACT’s 14 sites include 8 in Africa – the Gambia, Nigeria, Tanzania, Guinea, Niger, Malawi, Burkina Faso and DR Congo – and 6 in Asia – India (2), Cambodia, Bangladesh, Indonesia and Myanmar.

Dr Melanie Renshaw of the African Leaders Malaria Alliance will chair a project steering committee of representatives from the Asia-Pacific Leaders Malaria Alliance, WHO, malaria civil society organisations and academia that will advise the DeTACT management team as it implements activities to make TACTs available to malaria control and elimination campaigns worldwide.

DeTACT is the third of three DfID supported multi-country, multi-site trials (TRAC and TRACII) that have characterised artemisinin resistance and tested multi-drug resistant malaria treatments in SE Asia.

- Thank you, Chanaki Amaratunga and Mehul Dhorda for text and Supa-at (Ice) Asarath for photo

Similar stories

How did people in Europe and SE Asia experience the first COVID-19 wave?

An international team, led by Phaik Yeong Cheah, conducted an anonymous online survey from May-June 2020, asking 5,058 people in Thailand, Malaysia, United Kingdom, Italy and Slovenia to share their experiences. Anne Osterrieder and colleagues report the unequal impacts of public health measures, and the prevalence of ‘fake news’.

Recruitment surges in COPCOV COVID-19 prevention study

As high COVID-19 daily cases and highly transmissible variants risk overwhelming countries’ healthcare systems, COPCOV, the world’s last-standing large prophylaxis RCT, faces tight timelines to determine whether chloroquine/ hydroxychloroquine prevents COVID-19

Simple blood tests may help improve malaria diagnosis in clinical studies

About one-third of children diagnosed with severe malaria may instead have an alternative cause of illness, but simple blood tests could help researchers distinguish between the two and speed up research on new treatments.

OUCRU scientists identify combination of biological markers associated with severe dengue

Nguyen Lam Vuong, Sophie Yacoub & colleagues have identified a combination of biological markers in patients with dengue that could predict whether they go on to develop moderate to severe disease. Biomarkers are used to identify the state or risk of a disease in patients; these findings could aid the development of biomarker panels for clinical use and help improve triage and risk prediction in patients with dengue.

RECOVERY trial finds Regeneron’s monoclonal antibody combination reduces deaths for hospitalised COVID-19 patients who have not mounted their own immune response

The Randomised Evaluation of COVID-19 Therapy (RECOVERY) trial has demonstrated that the investigational antibody combination developed by Regeneron reduces the risk of death when given to patients hospitalised with severe COVID-19 who have not mounted a natural antibody response of their own.

RECOVERY trial finds aspirin does not improve survival for patients hospitalised with COVID-19

The RECOVERY trial was established as a randomised clinical trial to test a range of potential treatments for patients hospitalised with COVID-19. Patients with COVID-19 are at increased risk of blood clots forming in their blood vessels, particularly in the lungs. Between November 2020 and March 2021, the RECOVERY trial included nearly 15,000 patients hospitalised with COVID-19 in an assessment of the effects of aspirin, which is widely used to reduce blood clotting in other diseases. There was no significant difference in the primary endpoint of 28-day mortality